

China Inbound Macro by Region Q4 2023

Overview	Announced Amounts	\$44,005.1 ⁽¹⁾	Aggregate Amounts With maximum future payouts	\$64,442.1 ⁽²⁾	Volume	70
-----------------	--------------------------	----------------------------------	---	----------------------------------	---------------	-----------

Ranked by Announced Amounts in \$ millions

GCC	Volume	13	There were several multi-billion announced investments in manufacturing, renewable energy, mobility, NEVs and e-sports. There were also hundred million + investments in NEVs, logistics and healthcare; partnerships announced with stock exchanges both in KSA and in both Shenzhen and Hong Kong. Note, our analysis excludes 7 Chinese company partnerships with ACWA Power, the UAE's MoU on collaborations with Jiangsu Province and the circa \$7 billion currency swap between China and KSA as there were no specifics. Disclosed amounts more than filled the gap of banned USA VC and PE investments which historically have totalled some \$20-30 billion/year.
	Announced Amounts	20,280.0	
	With Currency Swap Amounts	27,210.0	
Asia	Volume	26	Volume spreading more widely throughout Asia: 12 in Hong Kong, 6 from East Asia, 5 from ASEAN and 3 from Central Asia (Kazakhstan and India). The 3 largest from Hong Kong represented nearly \$3 billion aggregate (1 in electronics, 2 in real estate). Japan had one large pharma deal, while Singapore had 2 mid-sized in logistics and in industrial parks. India expanded Chinese manufacturing.
	Announced Amounts	8,489.1	
	With Currency Swap Amounts	10,152.1	
Europe	Volume	24	Germany led with 16 investments; 4 by Netherlands and 2 by Switzerland; Denmark green methanol JV with Goldwind. German automotive (Audi/FAW plant at \$4.87 billion) and pharma (largest \$483 million) remain the most active sectors. Leapmotor (NEV) 20% stake for \$1.65 billion shows Netherlands expansive in NEVs. Swiss focus remains pharma.
	Announced Amounts	7,303.5	
	With Currency Swap Amounts	9,134.5	
UK	Volume	15	The most active quarter inbound from the UK into China that we have seen for a number of years. AstraZeneca (AZ) and GSK were both very active in volume as well as reported amounts. There were also 5 mid-sized/small financial services deals across banking, insurance and securities – both acquisitions and capital increases- and with BP, carbon credits and a shipping deal. INEOS had 3 deals including 2 sizeable JVs with no stated values. These could be of significant size.
	Announced Amounts	4,909.0	
	With Currency Swap Amounts	8,124.0	
North America	Volume	14	Volume was led by USA; Canada had only 1 small biotech deal. Despite the ban, there was still limited corporate activity with Carlyle selling its 28% stake to McDonalds USA (\$1.8 billion); Vanguard selling its Chinese operations to Ant Financial, Timkin also exiting China. Two pharma rights deals including one for \$800 million. Small deals/JVs in consumer. Mastercard finally launches. Two small funds deals launched. Note, removing the Carlyle Chinese exit drops the amount to \$1.3 billion – a fraction of prior periods.
	Announced Amounts	3,021.5	
	With Currency Swap Amounts	9,821.5	
Australia	Volume	1	A single inbound JV in biotech.
	Announced Amounts	ND	
Israel	Volume	1	A single inbound JV in biotech.
	Announced Amounts	ND	

Footnotes:

(1) 15 of the announced European transactions had no disclosed values; nor did 10 UK deals. Several of the transactions included are likely to be significant in size thus this number understated.

(2) Most of these are long term licensing rights deals in pharma.